OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs worldwide with a “Made in Taiwan” branding and to provide new treatment options for patients with unmet medical needs.
OBI is interested in commercializing its ADC technology platforms and looks forward to collaborating with biotech and pharmaceutical companies by enabling “first-in-class” and “best-in-class” therapeutic candidates for further development.